DLBCL MK-2140-011
Study #MK-2140-011Description
A Randomized, Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Zilovertamab Vedotin Plus R-CHP Versus Polatuzumab Vedotin Plus R-CHP in Treatment-naïve Participants With GCB Subtype of Diffuse Large B-cell Lymphoma.
Interested in this trial? Email [email protected].
Back To Clinical Trials